APMPEE is self-limiting with a generally good prognosis with the majority of affected patients achieving a visual acuity of 20/40 or better. Visual recovery typically takes 4 weeks, but can extend to 6 months in some patients. A recent review by Fiore T el al. analyzed 183 articles related to APMPPE and concluded that 25% of patients had a visual acuity of 20/50 or worse. Foveal involvement confers a worse visual prognosis. There is no current consensus on treatment although steroids have been utilized and reported to be beneficial in cases of foveal involvement and associated CNS vasculitis. Future studies are needed to evaluate dosage, duration, and effects of steroid treatment. All patients with a new diagnosis of APMPPE should receive a full neurologic and systemic work-up to evaluate for CNS vasculitis and other associated systemic conditions.
Aggressive therapy, early detection, very slow tapering of oral steroids and immunosuppressants are key to maintain good visual acuity. The prognosis of the disease was dependent on the duration and the number of recurrent episodes of inflammation.  A poor final visual acuity was predicted by a greater number of complications, older age at disease onset, a longer medium duration of the disease, prompt or delayed initiation of treatment, and greater number of recurrent episodes of inflammation. The better visual acuity at presentation, the more likely the final visual acuity would improve.